Dna aneuploidy and urothelial carcinoma: A meta-analysis Authors: Siying He, Miao Fu, Shuwei Fan, Pengfei Zhou, Junqi Wu Published: 2026 ABSTRACT BackgroundUrothelial carcinoma (UC) is regarded as the third most common cancer in adults, with a high incidence and mortality rate, and lacks specific tumor markers. With the advancement of technology, DNA ploidy analysis technology has become more convenient and efficient. Through meta-analysis of the correlation between DNA aneuploidy rate and UC prognosis, a more efficient UC prognosis indicator was discovered.MethodsThrough searching PubMed, Web of Science, Embase and Cochrane Library database, we were able to identify the studies evaluating the prognostic value of DNA aneuploidy in UC.ResultsIn all, 15 citations were included in this meta-analysis. Pooled results showed that DNA aneuploidy was significantly corrected with poor OS (HR = 4.32, 95% CI = 2.39-7.81, P < 0.001), poor DFS (HR = 1.84, 95% CI = 1.36-2.50, P < 0.001) and poor PFS (HR = 1.97, 95% CI = 1.37-2.83, P < 0.001) in UC patients. However, subgroup analysis revealed that DNA aneuploidy was associated with poor OS in Asian and American, but not in European. Correlation analysis of clinical pathological features suggested that DNA aneuploidy was related to the TNM stage, tumor grade, lymph node metastasis, tumor type and recurrence of UC.ConclusionOur meta-analysis showed the clinical value of DNA aneuploidy and its prognostic value in UC. Introduction Urothelial carcinoma (UC) is the most common tumor of the urinary system, with approximately 170,470 new cases each years, among which about 33,140 patients die.1 Patients with advanced or metastatic UC had a median overall survival (OS) of approximately 15 months from diagnosis, and their 5-year survival rate was only 18%.2 It is well known that UC is a multigenic malignant tumor originating from the urothelium, including bladder cancer, renal pelvis cancer, ureteral cancer and urethral cancer,3 and among these, bladder cancer accounts for 90% of the incidence of UC, which is the tenth most common cancer in the world.4 Currently, in clinical, although the prognosis of local UC is well, if it invades smooth muscle, the survival rate will significantly decrease.5 However, patients were often diagnosed in the middle or late stages of the disease. At the time of diagnosis, about 70-75% of patients show muscle infiltration, and more than 25% of cases are already muscle-infiltrating or metastatic UC.6 Therefore, early screening can effectively improve the prognosis of UC. The link between chromosomal abnormalities and cancer was first proposed by Theodor Boveri over 10 years ago, and since then, chromosomal abnormalities have been confirmed be almost ubiquitous in cancer and have gradually become a hallmark of human cancer, which is associated with poor prognosis, metastasis and therapeutic resistance.7,8 DNA is the material basis for the inheritance of living organisms and every normal cell has a fixed amount of DNA, which is generally measured in units such as DNA index (DI) or content (C). When the cells are in the G1/G0 phase, the DNA content of the cells id DI=1 or 2C, and while cells are in the cell proliferation phase, the DNA content can increase exponentially, with DI=2 or 4C. The reason why DNA ploidy analysis is more sensitive than conventional cytology is related to the working principle that DNA ploidy analysis determines the state of cells by measuring the multiples of DNA chromosomes, and the true essence of cell carcinogenesis lies in the rapid and unlimited proliferation of cells.9 When cells undergo carcinogenesis, the DNA content within the cells, as well as the distribution and arrangement of chromosomes within the cell nucleus, will change to varying degrees, and such changes occur in the earliest stage of cell carcinogenesis.10 The changes in the logarithm of a few chromosomes within the cell nucleus are difficult to assess with the naked eye, so measuring the changes in DNA content within the cell can be prioritized over discovering morphological changes. If the DNA content of a cell is to some extent greater than the maximum DNA content that can occur within a normal cell cycle (≥5C), it is determined that the cell has DNA ploidy abnormalities.11 Therefore, early screening of tumors can be carried out by detecting DNA ploidy. DNA ploidy analysis technology was reported to be applied in the research of UC as early as 20 years ago.12,13 Dimashkieh et al. 's research proposed that the sensitivity of FISH in detecting UC was 61.9% and the specificity was 89.7%, which was higher than that of cytological detection and could be used for the early screening of UC.14 Furthermore, studies have shown that DNA ploidy is associated with the tumor stage of upper urothelial carcinoma, but not with disease-specific survival (DSS).15 Based on these studies with different conclusions, we conducted the first meta-analysis based on DNA aneuploidy and the prognosis of UC. With the instrumentalization of DNA ploidy analysis, this technique has the advantages over previously conducted studies of high accuracy, good repeatability, simple and rapid operation, and low cost.16 The conclusion of our meta-analysis would be more helpful for the clinical promotion of DNA ploidy. However, p53 gene mutation as the most commonly detected somatic mutation in urothelial bladder cancer., have been shown in multiple studies that overexpressed p53 protein may lead to poor prognosis in bladder cancer.17,18 Experiments have proved that the number of DNA aneuploid cells was positively correlated with the expression intensity of p53, and the expression of p53 protein is related to the prognosis of superficial transitional cell carcinoma of the bladder.12,19 The fully automatic DNA image cell analyzer accurately quantified aneuploid cells by capturing all cells on the scanning slide, which has the advantages of low cost, simple and fast operation, high accuracy and good repeatability of the analysis results. Therefore, we collected studies exploring the correlation between DNA ploidy and the prognosis of UC and conducted a meta-analysis to estimate the potential prognostic value of DNA ploidy analysis technology. We also explored the correlation between the degree of DNA ploidy abnormalities and some other clinical indicators. Methods Publication search This meta-analysis fully adhered to the guidance of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA).20 We carried out a systematic search for relevant published studies in various electronic databases, including PubMed, Web of Science, Embase and Cochrane Library database up to June 30, 2025, using both MeSH search for keywords and full text. The searching terms were as following: (“urothelial/urothelium/bladder/renal pelvis/ureteral/ urethral cancer/carcinoma”) AND (“DNA ploidy/aneuploidy”, “cytometry”) There are no language application restrictions during the search process. In addition, we would also sort out relevant literature and research to look for more potential articles. Inclusion criteria Clinical studies that were considered to meet the conditions of this meta-analysis were based on the following criteria: 1) patients were diagnosed UC through histological methods, and samples were collected before any anti-cancer treatment, such as chemotherapy, radiotherapy, hormone therapy; 2) the study aims to evaluate overall survival (OS), disease-free survival (DFS), or progression-free survival (PFS) with the relationship of DNA content as the research objective; 3) the study provided Kaplan-Meier (K-M) curve to estimate the survival rate based on DNA content, or hazards regression (HR) and 95% confidence interval (CI) to explore the independent prognostic value of DNA content; 4) the study provided the relevant clinicopathological parameters. The exclusion criteria were as following: 1) studies that not based on human; 2) insufficient HRs or other data; 3) retrieved papers which were early reports of updated data in subsequent publications; 4) reviews, case reports or meta-analysis. Siying He and Shuwei Fan conducted literature retrieval and screened out the qualified studies according to the inclusion criteria. Miao Fu participated in the final decision to discuss if no consensus could be reached. Data extraction and quality detection Siying He and Shuwei Fan evaluated and collected data from these eligible articles with a predefined standard independently. The data extracted from studies included first author’s name, publication year, countries, number of patients, baseline characteristics, statistic method, DNA ploidy status, median followed-up month and survival data about OS, DFS and PFS. The Engauge Digitizer 12.1 software was used to extract data from K-M curve, when there was no HRs and its 95% CIs offered directly.21 Furthermore, subgroup analysis of the relationship between UC aneuploidy rate and tumor size, tumor grade, TNM stage, lymph node metastasis will also be conducted. Statistical analysis Statistical analyses were conducted in accordance with the recommendations of the Cochrane Collaboration Guidelines. The quality of included studies was evaluated by the Newcastle-Ottawa Scale (NOS),22 and NOS visualization was performed by Python. All statistical analysis were performed by using Stata 17 and some software packages needed to be installed to complete the analysis. “Metan” was used to assess the study effect, including pooled HR and 95% CI, and then “metanby” was applied to perform a stratified meta-analysis, according to different cancer types, ethnicities and followed up period. Furthermore, we used “metabias funnel” to evaluate the publication bias of our analysis. The prognostic value of DNA ploidy on OS, DFS, PFS was calculated by pooled HRs with 95% CIs, while the relationship between DNA ploidy and clinicopathological features was assessed by using odds ratios (ORs) with corresponding 95% CIs. Chi square-based Cochran Q test and I2 test were used to determine the heterogeneity among these eligible studies. I2 > 50% or P value < 0.05 was considered as significant heterogeneity, and a random-effect model should be adopted; otherwise, a fixed-effect model would be chosen. The influence of covariates was evaluated by regression analysis. The sources of heterogeneity could be analyzed by subgroup analysis. In addition, sensitivity and publication bias analysis were also conducted. P value < 0.05 was considered statistically significant when testing against a two-sided alpha of 0.05. Result Search results and research characteristics A total of 262 records were identified and 34 duplicate records were excluded. After scanning titles and abstracts, 78 articles remained and among the 78 articles, 2 were excluded due to non-human studies, 25 were excluded due to insufficient HRs or other data, 1 was excluded because the included patients were repeated in other studies, in addition, 9 clinical trials, 3 case reports, 21 reviews and 2 comment were excluded, and all these excluded studies were listed in Supplementary table 1 with reasons for transparency. The flowchart was shown in Fig. 1. Finally, 15 eligible studies were included in our meta-analysis.15,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 In order to determine the credibility of our meta-analysis results and find the cause of heterogeneity, we conducted NOS evaluation and visualization of the included studies, and the results are presented in Fig. 2. These eligible studies included 1656 patients, with postoperative followed-up period ranging from 24 months to 240 months. DNA ploidies were detected by cytometry and the characteristics of these eligible articles were listed in Table 1.Fig. 1Flow diagram of study selection.Fig 1 dummy alt textFig. 2Risk of bias summary figures. a Traffic light plot; b Summary bar chart.Fig 2 dummy alt textTable 1Characteristics of studies included in this meta-analysis.Table 1 dummy alt textAuthorYearCountryNo. of PatientFollowed-up monthAnalysisOutcomeNOSBlute1988Minnesota109180K-M CurveOS7Blomjous1988Netherland6160K-M CurveOS6Baladament1990Columbus50120K-M CurveDFS7Baladament1990Columbus22102K-M CurveOS6Lipponen1991Finland222240K-M CurveDFS7Wang1991China62132K-M CurveOS6Vita1991Italy61100K-M CurveOS7Hemstreet1991Oklahoma City88180K-M CurveOS7Norming1992Sweden71120K-M CurvePFS6Lipponen1993Finland448240K-M CurvePFS7Lee1994Korea93120K-M CurveOS7Russo1994Italy12824K-M CurvePFS7Wu1998China81108K-M CurvePFS7Rotterud2001Oslo94120K-M CurveDFS7Deliveliotis2005Greece66105MultivariateOS8K-M curve, Kaplan-Meier Curve; NOS, Newcastle-Ottawa Scale; OS, Overall survival; DFS, Disease-free survival; PFS, Progression-free survival. Flow diagram of study selection. Risk of bias summary figures. a Traffic light plot; b Summary bar chart. Table 1Characteristics of studies included in this meta-analysis.Table 1 dummy alt textAuthorYearCountryNo. of PatientFollowed-up monthAnalysisOutcomeNOSBlute1988Minnesota109180K-M CurveOS7Blomjous1988Netherland6160K-M CurveOS6Baladament1990Columbus50120K-M CurveDFS7Baladament1990Columbus22102K-M CurveOS6Lipponen1991Finland222240K-M CurveDFS7Wang1991China62132K-M CurveOS6Vita1991Italy61100K-M CurveOS7Hemstreet1991Oklahoma City88180K-M CurveOS7Norming1992Sweden71120K-M CurvePFS6Lipponen1993Finland448240K-M CurvePFS7Lee1994Korea93120K-M CurveOS7Russo1994Italy12824K-M CurvePFS7Wu1998China81108K-M CurvePFS7Rotterud2001Oslo94120K-M CurveDFS7Deliveliotis2005Greece66105MultivariateOS8K-M curve, Kaplan-Meier Curve; NOS, Newcastle-Ottawa Scale; OS, Overall survival; DFS, Disease-free survival; PFS, Progression-free survival. Characteristics of studies included in this meta-analysis. K-M curve, Kaplan-Meier Curve; NOS, Newcastle-Ottawa Scale; OS, Overall survival; DFS, Disease-free survival; PFS, Progression-free survival. Meta-analysis of DNA aneuploidy on OS/DFS/PFS A total of 8 eligible studies, involving 562 patients, were recruited to assess the impact of DNA aneuploidy rate on OS. The pooled HR and 95% CI indicated that a higher rate of DNA aneuploidy was significantly associated with poor OS in patients with UC (HR = 4.32, 95% CI = 2.39-7.81, P < 0.001), with a significant heterogeneity across these studies (I2 = 65.4%, P = 0.005) (Fig. 3a). In addition, 3 studies investigated the relationship between DNA aneuploidy rate and DFS, and 4 studies respectively examined the relationship between DNA aneuploidy rate and PFS. Due to the small number of studies and significant heterogeneity in the data, both of the DFS (I2 = 0%, P = 0.856) and PFS (I2 = 42.8%, P = 0.154) should be analyzed using the fixed-effect model. Finally, the results indicated that higher DNA aneuploidy were significantly associated with the shorter DFS (HR = 1.84, 95% CI = 1.36-2.50, P < 0.001) or the shorter PFS (HR = 1.97, 95% CI = 1.37-2.83, P < 0.001) (Fig. 3b-c).Fig. 3Forest plot of studies evaluating hazard ratios (HRs) of DNA aneuploidy and the prognosis of patients with urothelial carcinoma. a High rate of DNA aneuploidy and the overall survival (OS); b high rate of DNA aneuploidy and the disease-free survival (DFS); c high rate of DNA aneuploidy and the progression-free survival (PFS).Fig 3 dummy alt text Forest plot of studies evaluating hazard ratios (HRs) of DNA aneuploidy and the prognosis of patients with urothelial carcinoma. a High rate of DNA aneuploidy and the overall survival (OS); b high rate of DNA aneuploidy and the disease-free survival (DFS); c high rate of DNA aneuploidy and the progression-free survival (PFS). Subgroup analysis for OS In order to find the source of heterogeneity, the subgroup analysis of OS was performed (Table 2), and all 562 patients were classified based on cancer types, ethnicities and followed-up period (Fig. 4). Single study which assessed the relationship between the rate of DNA aneuploidy and OS in renal pelvis cancer was assessed in a single subgroup. Subgroup analysis showed that, high rate of DNA aneuploidy indicated to poor OS in bladder cancer (HR = 5.11, 95% CI = 2.43-10.75, P < 0.001).Table 2Subgroup analysis of pooled HRs for OS.Table 2 dummy alt textCategoriesNo. of studiesNo. of patientsPooled HR (95% CI)HeterogeneityFix/RandomP valueI2 (%)P valueOS85624.32 (2.39-7.81)< 0.00165.50.005Cancer type8Bladder cancer74535.11 (2.43-10.75)< 0.001670.006Other cancer11092.50 (1.55-4.03)<0.0010<0.001Ethnicity8Asian21556.88 (1.36-34.70)0.02071.80.06European31889.81 (2.37-40.56)0.00269.20.039American32192.34 (1.61-3.39)< 0.00100.91Follow-up period8<10 years42106.29 (1.95-20.92)0.00270.10.018≥10 years43523.35 (1.74-6.44)< 0.00160.70.054OS, overall survival; HR, hazard ratio.Fig. 4Subgroup analysis of pooled hazard ratios (HRs) for overall survival (OS). a Cancer type; b ethnicity; c follow-up period.Fig 4 dummy alt text Table 2Subgroup analysis of pooled HRs for OS.Table 2 dummy alt textCategoriesNo. of studiesNo. of patientsPooled HR (95% CI)HeterogeneityFix/RandomP valueI2 (%)P valueOS85624.32 (2.39-7.81)< 0.00165.50.005Cancer type8Bladder cancer74535.11 (2.43-10.75)< 0.001670.006Other cancer11092.50 (1.55-4.03)<0.0010<0.001Ethnicity8Asian21556.88 (1.36-34.70)0.02071.80.06European31889.81 (2.37-40.56)0.00269.20.039American32192.34 (1.61-3.39)< 0.00100.91Follow-up period8<10 years42106.29 (1.95-20.92)0.00270.10.018≥10 years43523.35 (1.74-6.44)< 0.00160.70.054OS, overall survival; HR, hazard ratio. Subgroup analysis of pooled HRs for OS. OS, overall survival; HR, hazard ratio. Subgroup analysis of pooled hazard ratios (HRs) for overall survival (OS). a Cancer type; b ethnicity; c follow-up period. In the subgroup analysis, we also found that in American races (HR = 2.34, 95% CI = 1.61-3.39, P < 0.001) and Asian (HR = 6.88, 95% CI = 1.36-34.70, P = 0.020), a higher rate of DNA aneuploidy was significantly associated with the shorter OS. Furthermore, depending on the followed-up period, it could be observed in the subgroup analysis that when the followed-up period over 10 years (HR = 3.35, 95% CI = 1.74-6.44, P < 0.001), the relationship between high rate of DNA aneuploidy and poor OS could be found. DNA aneuploidy and relative clinical pathological features To further obtain the clinical value of DNA aneuploidy, we investigated the correlation between the level of DNA aneuploidy and certain clinical parameters of UC (Table 3). DNA aneuploidy was significantly related with the TNM stage (OR = 5.45, 95% CI = 3.37-8.81, P < 0.001, random-effect model), tumor grade (OR = 6.84, 95% CI = 5.02-9.33, P < 0.001, fixed-effect model), tumor type (OR = 6.09, 95% CI = 4.12-9.01, P < 0.001, fixed-effect model), lymph node metastasis (OR = 3.86, 95% CI = 2.28-6.51, P < 0.001, fixed-effect model) and recurrence (OR = 2.34, 95% CI = 1.17-4.67, P = 0.016, fixed-effect model). Whereas through these included articles, there was no significant correlation between DNA aneuploidy and p21 expression (OR = 8.12, 95% CI = 0.75-88.46, P = 0.086, random-effect model). However, p21 was an important regulatory factor of the cell cycle to be involved in DNA replication, the relationship between p21 expression and DNA aneuploidy rate needed more research to confirm. Therefore, these corrections indicated that a high rate of DNA aneuploidy was associated with the advanced biological behavior of UC. In this study, the statistically significant impact of covariates on the malignancy degree and survival rate tumors was not analyzed.Table 3Analysis of outcomes by categories.Table 3 dummy alt textClinicopathological parametersNo. of studiesNo. of ParticipantsRisk of DNA aneuploidy OR (95% CI)Significant ZP valueHeterogeneity I2 (%)P valueModelTNM stage (III-IV vs I-II)1112435.45 (3.37-8.81)6.915< 0.00160.60.005Random effectTumor grade (3 vs 1-2)912406.84 (5.02-9.33)12.141< 0.00126.70.207Fixed effectTumor type (non-papillary vs papillary)48596.09 (4.12-9.01)9.039< 0.00100.870Fixed effectLymph node involvement (yes vs no)46313.86 (2.28-6.51)5.050< 0.00100.784Fixed effectRecurrence (yes vs no)21522.34 (1.17-4.67)2.4070.01600.331Fixed effectP21 (positive vs negative)21538.12 (0.75-88.46)1.7190.08684.40.011Random effect Table 3Analysis of outcomes by categories.Table 3 dummy alt textClinicopathological parametersNo. of studiesNo. of ParticipantsRisk of DNA aneuploidy OR (95% CI)Significant ZP valueHeterogeneity I2 (%)P valueModelTNM stage (III-IV vs I-II)1112435.45 (3.37-8.81)6.915< 0.00160.60.005Random effectTumor grade (3 vs 1-2)912406.84 (5.02-9.33)12.141< 0.00126.70.207Fixed effectTumor type (non-papillary vs papillary)48596.09 (4.12-9.01)9.039< 0.00100.870Fixed effectLymph node involvement (yes vs no)46313.86 (2.28-6.51)5.050< 0.00100.784Fixed effectRecurrence (yes vs no)21522.34 (1.17-4.67)2.4070.01600.331Fixed effectP21 (positive vs negative)21538.12 (0.75-88.46)1.7190.08684.40.011Random effect Analysis of outcomes by categories. Sensitivity analysis and publication bias In order to determine whether an individual study could affect the overall result, we performed sensitivity analysis. The sensitivity analysis results demonstrated that the individual study had no influence on the result of meta-analysis (Fig. 5). In addition, Begg’s test, which was more suitable for small sample size detection, and funnel plots were performed to evaluate the publication bias of our meta-analysis, and the results showed that there was no publication bias existed in studies on association between the rate of DNA aneuploidy and OS (P = 0.053), DFS (P = 0.296) and PFS (P = 0.308).Fig. 5Sensitivity analysis and Begg’ funnel plots of the meta-analysis. a Sensitivity analysis of overall survival (OS); b Begg’s funnel plot of OS; c sensitivity analysis of disease-free survival (DFS); d Begg’s funnel plot of DFS; e sensitivity analysis of progression-free survival (PFS); f Begg’s funnel plot of PFS.Fig 5 dummy alt text Sensitivity analysis and Begg’ funnel plots of the meta-analysis. a Sensitivity analysis of overall survival (OS); b Begg’s funnel plot of OS; c sensitivity analysis of disease-free survival (DFS); d Begg’s funnel plot of DFS; e sensitivity analysis of progression-free survival (PFS); f Begg’s funnel plot of PFS. Discussion UC is the third most common malignant tumor in adults,1 which mainly affected the elder men.37,38 The early symptoms of UC are not typical but progress rapidly and have a high degree of malignancy, so UC still faces many challenges in diagnosis and treatment.39 Some new drugs, such as immune checkpoint inhibitors (ICIs), tyrosine kinase inhibitors (TKIs) targeting fibroblast growth factor receptors (FGFR), and antibody-drug conjugates (ADCs) targeting Nectin-4, are still in the clinical research stage.40,41 UC lacks specific tumor markers, so that a non-invasive method was vital for the prognosis judgment treatment monitoring. DNA ploidy analysis provides an objective and quantitative evaluation index for malignant tumors, which has unique clinical application value in the following aspects: First, DNA ploidy analysis is more sensitive than traditional cytology, which improve the early detection rate, with objective quantitative criteria and clear treatment threshold. Second, DNA ploidy analysis can improve the positive rate of biopsy, without unnecessary trauma and waste of medical resources, especially in "atypical" tumor cells. Third, DNA ploidy analysis can assess tumor aggressiveness and guide treatment strategies. The 5-year survival rate of breast cancer patients with DNA aneuploidy is 68%, which is much lower than that of diploid (88%) and tetraploid (100%).42 In the management of prostate cancer, DNA ploidy and PTEN protein detection can more accurately identify high-risk groups in patients and help doctors intervene immediately.43 Compared with molecular/genomic techniques, DNA ploidy analysis has lower costs and can be standardized; compared with cytopathological techniques, DNA ploidy analysis can be quantitative and does not rely on pathologists, nor does it require a special laboratory. Although the role of aneuploidy as an independent prognostic parameter for UC has been widely studied over the past few decades, the results remain controversial.15 Based on the advantages of DNA ploidy and the current problems faced by UC treatment, we conducted a meta-analysis on its clinical significance in the field of UC prognosis. Our meta-analysis was the first study to evaluate the association between DNA aneuploidy and prognostic value in UC through drawing data from 15 published studies, involving 1656 patients. The HRs included in our meta-analysis were all derived from K-M curve, which were already adjusted with smaller bias. The research results supported DNA aneuploidy as an important predictor of OS, DFS and PFS in patients with UC. Further, clinicopathological features research indicated that the frequency of DNA aneuploidy was significantly correlated with certain prognostic factors, such as TNM stage, tumor grade, lymph node metastasis, tumor type and recurrence rate. Patients with diploid tumors benefited from a significantly reduce risk for cancer recurrence and death (18% and 25%, respectively). However, our study did not confirm the correlation between p21 and DNA ploidy (OR = 8.12, 95% CI = 0.75-88.46, P = 0.086). Furthermore, we performed subgroup analysis on heterogeneity of the meta-analysis, and we found that it might be due to the different types of UC, the geographical differences and the length of follow-up period. However, the number of researches included was small, and there might be unpublished negative results, we used Begg’s test to verify that the risk of publication bias was low. Our meta-analysis confirmed the correlation between DNA aneuploidy and poor prognosis of UC, which might be related to the following reasons: (1) Genomic instability increased mutation rates, which could lead to drug-resistant and highly invasive subclones.44 (2) Chromosomal imbalance changed key gene measurement. For example, amplification of 1q and 8q regions could increase the expression of oncogenes (MYC and EGFR), whereas 17p and 10q regions could inactivate tumor suppressor genes (TP53 and PTEN).45 (3) Abnormal chromosome numbers could trigger sustained stress through mitotic checkpoints to impair DNA damage repair and apoptosis, and to promote survival of genetically erroneous cells.46 (4) Aneuploid tumors were often accompanied by metabolic changes to keep an immunosuppressive environment for escaping immune attack.47 (5) Some subclones in hyper aneuploid tumors might be naturally resistant to chemotherapy, radiotherapy, or targeted therapy, leading to a poor prognosis 48. Many genes had been confirmed to be involved in the occurrence of DNA aneuploidy. Some genes caused DNA aneuploidy by inducing cell cycle arrest, such as MLN8237,49 while others affect the migration and invasion abilities of tumor cells by altering the cytoskeleton, resulting in the generation of DNA aneuploidy, such as ORP3, TKS5 and GJB3.50, 51, 52 In addition, Bacillus Calmette-Guérin (BCG) could be used for UC therapy, and the incidence of aneuploidy after BCG treatment was lower.53 Due to the biological and clinical values of DNA ploidy, it should be focused on during therapeutic planning. In aneuploidy UC, the treatment approach had undergone significant changes from mainly local chemotherapy-based methods to more personalized, biomarker-driven strategies integrating gene-targeted therapy.54 Our research was the first to employ the meta-analysis method to investigate the relationship between DNA ploidy and the prognosis of UC. The advantage of this analysis lied in its in-depth literature review and qualified statistical methods, which provided genuine results for our conclusion. However, this meta-analysis still had some limitations. First of all, the classification criteria of DNA ploidy results were not clear in some of the included studies. Secondly, the number of our included articles was small, and the sample size was small, which might lead to unreliable assessment of heterogeneity and invalidity of publication bias. Thirdly, the studies we included were from 12 countries in Asia, America, and Europe, which would increase the complexity of publication bias and might have little clinical value in our region. So far, the limitations should be adopted and considered carefully. This field required further research. Therefore, we would collect a larger sample size and conduct longer-term follow-ups. We would also validate the value of DNA aneuploidy in the prognosis of UC in more multi-center studies in the future. Conclusion This meta-analysis indicated that a high rate of DNA aneuploidy was significantly associated with a poor prognosis of urothelial carcinoma. During the process of UC progression, the rate of DNA aneuploidy increased, and at the same time, the metastasis rate and recurrence rate of UC also rase. DNA ploidy analysis technology, as a non-invasive and stable efficient method, hold great potential in the early diagnosis and treatment monitoring of UC. Moreover, the related pathways of DNA aneuploidy formation also provided new ideas for gene-targeted therapy. Funding This study was supported by Project of Jinhua Hospital[No: JY2022-6-12], Province Public Welfare Fund Research Project Analysis Test Project[No: LTGC24H200004], Jinhua Science and Technology Plan Project Social Development Key Project[No: 2023-3-105] and Jinhua Municipal Science and Technology Plan Project Social Development Major Project[No: 2023-3-067]. Declaration of competing interest None of the authors have any competing interests in the manuscript.